His PhD in Chemometrics and Artificial Intelligence from the ETH Zurich labs of Dr. Stoessel, plus his Board Certification in Cell Therapies from Mount Sinai, make him a chemical engineer. David is a FINRA Series 7, 63, 15 and 55 certified Healthcare Investment Banker. David has over 12 years of Healthcare Investment Banking expertise advising on M&A, project finance, capital raising and unique situations. For financial institutions, healthcare institutional investors, and strategic partners, David's customers have completed over 100 Healthcare Investment Banking transactions since 2008. David founded the AI Pathology platform in 2012 at Mount Sinai Hospital in New York and sold it to Philips in 2021. David was VP of Finance and Investment Strategy at ImClone Systems and Managing Director of Healthcare Banking at ThinkEquity. His career began at Novartis with Glivec® (Imatinib) and Pfizer with Rebif® (interferon beta-1a for MS) and Macugen.

Official website: htts://davidsans.co/